

REVIEW ARTICLE

Harnessing Lycopene: A Comprehensive Review of its Molecular Mechanisms and Chemotherapeutic Potential in Cancer Management

Sana Jameel ¹, Amreen Fatima ¹, Muzamil Liakat Mir ¹, Faiqua Haque ¹, Suhaima Safdar ¹, Nuzhat Parveen ², Mohd Aarim ³, Sadik Tyagi ⁴, G. G. H. A. Shadab ^{1,*}

ABSTRACT: Lycopene, a naturally occurring carotenoid predominantly found in tomatoes, has garnered significant attention for its potent chemopreventive and chemotherapeutic properties. Its primary mechanism of action is often attributed to its exceptional antioxidant capacity, particularly its ability to neutralize singlet oxygen and protect cellular DNA from oxidative damage. However, emerging evidence suggests that its anticancer effects extend far beyond simple radical scavenging. This review synthesizes current knowledge on the multifaceted molecular mechanisms through which lycopene exerts its effects. We explore its role in modulating key signaling cascades, including the induction of cell cycle arrest at critical checkpoints and the activation of both intrinsic and extrinsic apoptotic pathways. Furthermore, the compound influences the expression of sex steroid hormone receptors, regulates the insulin-like growth factor (IGF) system, and inhibits pro-inflammatory mediators. By targeting these critical pathways, lycopene demonstrates efficacy against a range of malignancies, including prostate, breast, ovarian, and cervical cancers. Given the considerable cost and adverse effects associated with conventional chemotherapeutics, the exploration of naturally derived, safe, and cost-effective compounds like lycopene is of paramount importance. This review aims to consolidate the existing evidence on lycopene's molecular targets, providing a foundation for its potential integration into future cancer management strategies.

Keywords: Lycopene, Cancer Chemoprevention, Apoptosis, Signal Transduction, Oxidative Stress, Molecular Targets

Received: 18 November 2025; Revised: 10 January 2026; Accepted: 02 February 2026; Published Online: 11 February 2026

1. INTRODUCTION

Lycopene, a lipophilic, red tetraterpenoid pigment, stands as

one of the most ubiquitous and extensively studied members of the carotenoid family. This naturally occurring compound is synthesized by plants and microorganisms, serving critical physiological roles in photosynthesis and photoprotection. In the human diet, lycopene is predominantly obtained from red-colored fruits and vegetables, with tomatoes and tomato-based products representing its most significant dietary reservoir. Other notable sources include watermelon, pink grapefruit, papaya, and pink guava [1]. Its distinctive deep red hue arises from its unique molecular structure, which features an extended system of conjugated double bonds that selectively absorbs visible light in the longer wavelength region.

Beyond its function as a natural pigment, lycopene has

¹ Cytogenetics & Molecular Toxicology Laboratory, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh 202002, UP, India.

² Women's College, Zoology Section, Aligarh Muslim University, Aligarh 202002, UP, India.

³ Department of Radiotherapy, JNMC, Aligarh Muslim University, Aligarh, 202002, U.P., India.

⁴ Department of Biochemistry, Aligarh Muslim University, Aligarh, U.P., India.

*Author to whom correspondence should be addressed:
gghas.amu@gmail.com (G. G. H. A. Shadab)

garnered considerable scientific interest due to its exceptional biological activities, most notably its potent antioxidant capacity. Unlike many other dietary carotenoids, lycopene lacks provitamin A activity, yet it compensates for this through its remarkable efficacy as a singlet oxygen quencher and free radical scavenger. Upon ingestion, lycopene is incorporated into lipoproteins, primarily low-density lipoproteins, and accumulates in various human tissues, including the adrenal glands, liver, testes, and prostate [2, 3]. Its concentration in human plasma, typically around 0.7 μM , reflects its bioavailability and underscores its potential systemic relevance. This introduction establishes the foundational context for understanding lycopene as a bioactive food constituent with profound implications for human health, particularly in the context of cancer prevention and therapy.

2. LYCOPENE CHEMISTRY

From a structural perspective, lycopene is a symmetrical, linear acyclic isomer of β -carotene, classified chemically as a tetraterpene composed of eight isoprene units. Its molecular formula is $\text{C}_{40}\text{H}_{56}$, with a molecular weight of 536.85 g/mol, and it is registered under the Chemical Abstracts Service number 502-65-8. The compound predominantly exists in the

all-trans configuration under natural conditions, though isomerization to various cis forms can occur during food processing or within the physiological environment. The systematic chemical name for all-trans-lycopene is (all-E)-2,6,10,14,19,23,27,31-octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene, though it is more commonly referred to by its trivial names, including ψ , ψ -carotene.

Figure 1 provides a schematic representation of the lycopene molecule, highlighting its characteristic long, linear structure. The molecule contains eleven conjugated double bonds situated centrally, with two additional unconjugated double bonds at each terminal end. This arrangement constitutes the longest conjugated system among all naturally occurring carotenoids. Each double bond within this extended π -electron network reduces the energy gap required for electron transitions, enabling the molecule to absorb light at progressively longer wavelengths. As a result, lycopene absorbs predominantly in the visible spectrum's blue-green region, which imparts its characteristic red appearance. The figure also typically includes annotations indicating the major dietary sources of lycopene and summarizing key factors that influence its bioavailability, such as thermal processing, which promotes cis-isomerization, and the presence of dietary lipids, which facilitate micellar solubilization and intestinal absorption.




Fig. 1. Chemical structure of lycopene. The molecule is a linear, acyclic tetraterpene with eleven conjugated double bonds, accounting for its red color and potent singlet oxygen quenching capacity.

3. LYCOPENE AS A NATURAL ANTIOXIDANT

The antioxidant properties of lycopene are unparalleled among lipophilic natural antioxidants. Comparative studies have consistently demonstrated that lycopene exhibits a singlet oxygen quenching rate constant nearly twice that of β -carotene and an order of magnitude greater than that of α -tocopherol [4]. This exceptional quenching ability is directly correlated with its molecular structure; the extended system of conjugated double bonds allows for efficient energy transfer from excited singlet oxygen molecules, effectively neutralizing them before they can cause oxidative damage to cellular components. The antioxidant capacity of lycopene manifests through its ability to inhibit lipid peroxidation at its initiation stage, protect low-density lipoproteins from oxidative modification, and safeguard critical biomolecules such as DNA, proteins, and membrane lipids.

The physiological relevance of lycopene's antioxidant activity extends beyond direct radical scavenging. Research has shown that lycopene can modulate endogenous antioxidant defense systems, effectively enhancing the body's intrinsic capacity to counter oxidative stress. In experimental models of lipopolysaccharide-induced oxidative stress, lycopene supplementation was found to elevate total antioxidant status and improve high-density lipoprotein-associated paraoxonase-1 function, while simultaneously downregulating circulating levels of inflammatory mediators [5]. At the molecular level, lycopene has been observed to upregulate heme oxygenase-1 mRNA expression at concentrations of 50 and 100 μ M, though its effects on inducible nitric oxide synthase and cyclooxygenase-2 expression appear to be context-dependent [6].

Furthermore, the anti-inflammatory dimensions of lycopene's activity have been elucidated in models of neuroinflammation. In the context of β -amyloid-induced inflammation, lycopene administration effectively attenuated the elevation of proinflammatory cytokines, including tumor necrosis factor- α , interleukin-1 β , and interleukin-6 β , while also reversing the expression of β -amyloid 1-42 [7]. This anti-neuroinflammatory effect extends to the mitigation of mitochondrial dysfunction, with lycopene demonstrating the capacity to suppress the activation of nuclear factor- κ B and caspase-3 in cerebral tissues [8]. Collectively, these findings position lycopene not merely as a passive antioxidant but as an active modulator of redox homeostasis and inflammatory signaling.

4. LYCOPENE AS AN ANTI-CANCER AGENT

The transition from antioxidant to anti-cancer agent is predicated upon lycopene's ability to intervene at multiple stages of the carcinogenic process. Unlike many conventional chemotherapeutic agents that target a single pathway, lycopene exerts pleiotropic effects that collectively disrupt the hallmarks of cancer. At the cellular level, lycopene has been demonstrated to induce cell cycle arrest at

distinct checkpoints, with the specific phase of arrest often being concentration-dependent. Lower concentrations primarily influence lipid peroxidation and oxidative stress parameters, while higher concentrations induce G₂/M phase arrest through the induction of DNA damage, ultimately culminating in cell cycle arrest followed by apoptosis [6]. The anti-proliferative actions of lycopene are mediated through the regulation of key signaling cascades. It interferes with the expression of lipoxygenase and cyclooxygenase enzymes, disrupts the activation of transcription factors such as nuclear factor- κ B and activator protein-1, and modulates mitogen-activated protein kinase signaling pathways [6]. These molecular interventions collectively contribute to the suppression of inducible nitric oxide synthase expression and the attenuation of inflammatory signaling that often fuels tumor progression.

Epidemiological and experimental evidence has consistently linked lycopene intake with reduced risk across a spectrum of malignancies. Dietary lycopene consumption has been associated with decreased prostate tumor aggressiveness, inhibition of breast cancer cell proliferation, and protective effects against ovarian and cervical carcinomas [11, 12]. Serum lycopene levels have been inversely correlated with the risk of bladder cancer, upper digestive tract cancers, and oral leukoplakia, suggesting a systemic protective effect. In specific cancer types, lycopene has demonstrated efficacy in reducing the proliferation of androgen-dependent prostate tumors in men and hormone-sensitive breast and endometrial tumors in women [12].

In vitro studies have provided mechanistic insights into these epidemiological observations. Lycopene treatment was found to arrest cell cycle progression in human lung adenocarcinoma A549 cells [13]. A comprehensive evaluation of lycopene's effects across multiple human cancer cell lines, including T-84, HT-29, MCF-7, and DU-145, revealed that lycopene induced cell cycle arrest and reduced cell viability in a time-dependent manner, with the most pronounced effects observed after 96 hours of exposure [14]. Furthermore, lycopene has been shown to enhance the anti-proliferative and pro-apoptotic effects of capsaicin in human prostate cancer cell lines, including LNCaP, PC3, PC3-AR2, and DU-145, suggesting potential synergistic interactions with other bioactive compounds [15].

The anti-cancer activity of lycopene extends across diverse cancer cell types, with dose-dependent growth inhibition observed in human colon carcinoma, erythroleukemia, and Burkitt's lymphoma cells [16]. While the inhibitory effect on chronic lymphoblastic leukemia cells was only evident at the highest tested concentration of 4 μ M, this underscores the importance of achieving adequate tissue levels [17]. Pro-apoptotic and anti-proliferative activities have also been documented in T-lymphoblast cells, further confirming lycopene's broad-spectrum anti-cancer potential [18].

5. LYCOPENE TARGETS FREE RADICALS GENERATED DURING OXIDATIVE STRESS

Reactive oxygen species constitute a diverse group of highly reactive molecules that include oxygen free radicals such as superoxide anion, hydroxyl radical, peroxy radical, and alkoxy radical, alongside non-radical species like hydrogen peroxide and singlet oxygen [19]. These species are continuously generated as byproducts of aerobic metabolism, with mitochondrial respiration serving as the principal endogenous source. Under normal physiological conditions, the production of ROS is balanced by complex antioxidative defense mechanisms that maintain cellular redox homeostasis [20]. However, when this equilibrium is disrupted, a state of oxidative stress ensues, characterized by excessive ROS accumulation and consequent damage to genomic DNA, lipids, and proteins [21-24].

The cellular defense against oxidative stress relies upon an integrated network of antioxidant enzymes and small molecule scavengers. Key components of this system include superoxide dismutase, catalase, the glutathione system encompassing glutathione, glutathione reductase, glutathione peroxidase, and glutathione transferase, the thioredoxin system, and non-enzymatic antioxidants such as vitamins E and C [25].

Figure 2 presents a schematic overview of lycopene's role as an antioxidant and redox modulator. The illustration delineates the dual sources of ROS generation, namely mitochondrial respiration and exogenous insults, and depicts the cascading oxidative damage inflicted upon DNA, lipids, and proteins. The figure further illustrates the endogenous antioxidant systems, including superoxide dismutase,

catalase, glutathione, thioredoxin, and vitamins C and E, which collectively neutralize ROS. Within this framework, lycopene is shown to exert its protective effects at multiple points: quenching singlet oxygen directly, inhibiting the propagation of lipid peroxidation, and improving systemic antioxidant status. The schematic uses upward arrows to denote lycopene-induced enhancement of total antioxidant capacity and paraoxonase-1 function, while downward arrows indicate the reduction of malondialdehyde and inflammatory mediators, providing a visual synthesis of lycopene's multifaceted antioxidant mechanisms.

Plant-derived phytochemicals, including lycopene, have been recognized for their capacity to mitigate oxidative stress and thereby reduce the risk of chronic diseases such as cancer [26]. Lycopene acts at multiple stages of carcinogenesis, inhibiting both the initiation and proliferation phases while also promoting cancer cell differentiation and apoptotic cell death [27]. The extensive antioxidant potential of carotenoids positions them as critical dietary components for human health, with β -carotene similarly recognized for its protective effects against cancer and cardiovascular disease [28]. Dietary intake of fresh fruits, vegetables, and herbs effectively enhances plasma antioxidant capacity, reflecting the cumulative benefits of these phytochemicals [29]. Supplementation studies have demonstrated that both natural and synthetic forms of lycopene reduce lipid peroxidation and oxidative stress, with synthetic lycopene exhibiting enhanced bioavailability and greater efficacy against oxidative stress [30].




Fig. 2. Schematic representation of lycopene as an antioxidant and redox modulator. Lycopene quenches singlet oxygen, inhibits lipid peroxidation, and enhances systemic antioxidant status by increasing total antioxidant capacity and paraoxonase-1 function while reducing malondialdehyde levels and inflammatory mediators.

Additional mechanistic insights reveal that polyphenols and flavonoids, compounds often co-consumed with lycopene in plant-based diets, inhibit pro-inflammatory gene expression through the suppression of I κ B phosphorylation, thereby preventing nuclear factor-kappa B transactivation and restoring transrepressive pathways via histone deacetylase activation [26, 31]. In experimental models, the chemopreventive efficacy of dietary phytochemicals has been further substantiated by the significant reduction in malondialdehyde production and carcinogenesis following supplementation with plant-derived compounds [32].

6. EFFECT OF LYCOPENE ON PROINFLAMMATORY CYTOKINES

The tumor microenvironment is characterized by a complex network of cytokines that orchestrate inflammatory responses and influence cancer progression. In cervical tumors, the mRNA expression of several cytokines, including tumor necrosis factor-alpha, interleukin-1 α , interleukin-6, interleukin-10, and interferon-gamma, has been detected, implicating these mediators in disease pathogenesis [33, 34]. Tumor necrosis factor-alpha, in particular, has been identified as a key promoter of metastasis and angiogenesis, suggesting its critical role in cervical cancer progression [33, 34]. This cytokine has also been implicated in the regulation of human papillomavirus infection, with multiple *in vivo* and *in vitro* studies demonstrating its involvement in viral pathogenesis [35].

Tumor necrosis factor-alpha exemplifies the dualistic nature of cytokine function, exhibiting both protective antiviral effects and cancer-promoting activities depending on the context [36, 37]. Previous investigations have established a clear link between tumor necrosis factor-alpha and the development of human papillomavirus-associated cervical tumors, highlighting the importance of this cytokine in virus-driven carcinogenesis. Furthermore, elevated levels of tumor necrosis factor-alpha and other cytokines have been detected in cervicovaginal washings from patients with cervical carcinoma, providing direct evidence of local inflammatory dysregulation in this malignancy [38].

Interleukin-10, an immunosuppressive cytokine, contributes to tumor immune evasion by downregulating type-1 cytokine responses. In human papillomavirus 16-positive cervical carcinoma cells, *in vitro* treatment with interleukin-10 increases the mRNA expression of the viral E7 early gene, thereby potentially enhancing oncogene expression [34]. Notably, cervical cancer cells, in contrast to normal cervical epithelial cells, have been reported to produce interleukin-10 and transforming growth factor-beta, with their expression levels increasing during the transition from carcinoma *in situ* to invasive cancer [34]. These observations underscore the profound alterations in cytokine signaling that accompany cervical carcinogenesis.

Figure 3 provides a detailed mechanistic depiction of lycopene's impact on cell cycle regulation and mitochondrial apoptosis in cancer cells. The figure illustrates the dual-phase

cell cycle arrest induced by lycopene, with G₀/G₁ arrest occurring at standard concentrations and G₂/M arrest at higher doses. These effects are mediated through the downregulation of cyclin D1, cyclin E, and cyclin-dependent kinases 2, 4, and 6, coupled with the upregulation of the cyclin-dependent kinase inhibitors p21, p27, and the tumor suppressor p53. Concurrently, lycopene promotes mitochondrial-dependent apoptosis by upregulating the pro-apoptotic protein Bax, downregulating the anti-apoptotic protein Bcl-2, inducing the loss of mitochondrial transmembrane potential, and triggering the release of cytochrome c, which subsequently activates caspase-9 and caspase-3. These molecular events culminate in apoptosis, as demonstrated in representative cancer cell lines including LNCaP, MCF-7, HT-29, A549, and Jurkat E6. By illustrating the convergence of cell cycle regulation and apoptotic signaling, Figure 3 provides a comprehensive visual framework for understanding lycopene's anti-cancer mechanisms at the cellular and molecular levels.

7. MOLECULAR TARGETS OF LYCOPENE

The anti-cancer efficacy of lycopene is underpinned by its remarkable capacity to interact with a diverse array of molecular targets that govern cellular proliferation, survival, and malignant transformation. Unlike conventional chemotherapeutic agents that typically act upon a single molecular entity, lycopene exerts its effects through a network of interconnected signaling pathways, thereby orchestrating a multifaceted anti-tumor response. This section delineates the principal molecular targets through which lycopene mediates its chemotherapeutic effects, encompassing cell cycle regulatory proteins, mitochondrial apoptotic machinery, sex steroid hormone receptors, the insulin-like growth factor system, and key signal transduction cascades.

7.1. Cell Cycle Regulatory Proteins

One of the primary mechanisms through which lycopene exerts its anti-proliferative effects is the modulation of cell cycle regulatory proteins. Lycopene possesses the intrinsic capacity to arrest cell cycle progression, enhance apoptotic cell death, and suppress cellular proliferation, all of which are mediated through significant alterations in the expression and activity of key cell cycle regulators [14]. The ability of lycopene to suppress proliferation and induce cell cycle arrest in prostate cancer cells has been convincingly demonstrated in both *in vitro* and *in vivo* experimental systems [39]. In a panel of tumor cell lines, including MCF-7 breast adenocarcinoma cells, T84 colon carcinoma cells, DU145 prostate cancer cells, and HT-29 colorectal adenocarcinoma cells, lycopene treatment consistently induced G₀/G₁ phase arrest followed by the initiation of apoptosis [14, 40].

The biological significance of cell cycle arrest is further underscored by the observation that G₀/G₁ arrest is reversible

upon treatment cessation, allowing cell proliferation to resume, whereas G₂/M arrest more frequently culminates in irreversible apoptosis [41]. This distinction highlights the importance of achieving adequate lycopene concentrations to induce the more therapeutically desirable G₂/M arrest. At the molecular level, lycopene has been shown to downregulate the expression of several cell cycle-promoting proteins, including cyclin E, cyclin D1, cyclin D3, cyclin-dependent kinase 2, and cyclin-dependent kinase 4. Concurrently, lycopene modulates the expression of apoptosis-related proteins, with a consistent reduction in Bcl-2 levels observed across multiple cancer cell lines. A particularly significant finding is the alteration in the phosphoinositide 3-kinase/Akt signaling axis, with lycopene treatment leading to decreased phospho-Akt levels accompanied by increased expression of the tumor suppressor p53, the cyclin-dependent kinase inhibitors p21 and p27, the pro-apoptotic protein Bax, and a consequent elevation in the Bax to Bcl-2 ratio [42-45].

Figure 4 presents a comprehensive schematic integrating the anti-oxidative, anti-proliferative, and anti-

metastatic properties of lycopene. The figure visually synthesizes the interconnected mechanisms through which lycopene exerts its protective effects, depicting the convergence of antioxidant activity, cell cycle regulation, apoptotic induction, and inhibition of metastatic processes. It illustrates how lycopene simultaneously targets multiple nodes within the cellular signaling network, thereby creating a coordinated anti-cancer response that is greater than the sum of its individual parts.

Additional investigations have further refined our understanding of lycopene's cell cycle effects, demonstrating that lycopene can induce G₁/S phase arrest through the coordinated downregulation of cyclin D1 and cyclin E, alongside the upregulation of p27 and cyclin A [42-47]. These findings collectively establish that lycopene's anti-proliferative effects are mediated through precise molecular targeting of the cell cycle machinery, with the specific pattern of cell cycle protein modulation being dependent upon both the concentration of lycopene and the particular cancer cell type under investigation.




Fig. 3. Lycopene-induced cell cycle arrest and mitochondrial apoptosis in cancer cells. Lycopene induces G₀/G₁ and G₂/M phase arrest through modulation of cyclins, cyclin-dependent kinases, and their inhibitors, while promoting mitochondrial apoptosis via Bax upregulation, Bcl-2 downregulation, cytochrome c release, and caspase activation.




Fig. 4. Integrated overview of the anti-oxidative, anti-proliferative, and anti-metastatic properties of lycopene. The figure illustrates how lycopene simultaneously targets multiple pathways, including free radical scavenging, cell cycle regulation, apoptotic induction, and inhibition of metastatic processes.

7.2. Mitochondrial Function and Apoptotic Pathways

Beyond its effects on cell cycle progression, lycopene exerts profound effects on mitochondrial function, a critical determinant of cellular energy metabolism and apoptotic susceptibility. When human LNCaP prostate cancer cells were treated with lycopene, a significant decrease in mitochondrial function was observed, characterized by a reduction in mitochondrial transmembrane potential [48]. This loss of mitochondrial membrane integrity serves as a critical checkpoint in the intrinsic apoptotic pathway, leading to the release of mitochondrial cytochrome c into the cytosol. Once released, cytochrome c associates with apoptotic protease activating factor-1 to form the apoptosome, which subsequently activates caspase-9 and downstream effector caspases, ultimately culminating in programmed cell death. This mitochondrial mechanism of action is particularly significant because it represents a cell-intrinsic apoptotic pathway that can be engaged independently of death receptor signaling, providing an alternative route to cell death in tumors that may have developed resistance to extrinsic apoptotic signals.

7.3. Sex Steroid Hormone Receptors

Lycopene's molecular targeting repertoire extends to the

modulation of sex steroid hormone signaling, a finding of particular relevance for hormone-sensitive malignancies. Estrogens and androgens play pivotal roles in the pathogenesis of breast, prostate, and endometrial carcinomas, with these hormones acting through their cognate receptors to promote cellular proliferation and survival. Lycopene has been demonstrated to inhibit 17β -estradiol-induced proliferation of breast and endometrial cancer cells through mechanisms mediated by both estrogen receptor α and estrogen receptor β [49]. This dual receptor targeting suggests that lycopene may exert its effects through direct interference with estrogen receptor signaling rather than through simple antioxidant mechanisms. The implications of this finding are substantial, as they position lycopene as a potential dietary intervention for hormone-dependent cancers, possibly complementing existing endocrine therapies.

7.4. Insulin-Like Growth Factor System

The insulin-like growth factor system represents another critical molecular target through which lycopene exerts its anti-cancer effects. Elevated plasma levels of insulin-like growth factor-I have been consistently associated with an increased risk of developing various types of carcinomas, establishing this growth factor axis as a significant cancer risk factor [50]. Lycopene has been shown to significantly

attenuate insulin-like growth factor-I-induced proliferation in lung, prostate, breast, and endometrial cancer cells through a dual mechanism involving the elevation of insulin-like growth factor-binding protein-3 levels and the downregulation of insulin-like growth factor-I receptor expression [51-53]. Insulin-like growth factor-binding protein-3 functions as a growth inhibitory protein by sequestering insulin-like growth factor-I, thereby preventing its interaction with the receptor. Simultaneously, the reduction in receptor expression diminishes cellular responsiveness to circulating growth factors. This coordinated modulation of both ligand availability and receptor sensitivity represents a sophisticated mechanism through which lycopene can dampen growth factor signaling in neoplastic cells.

7.5. Signal Transduction Pathways

Lycopene's influence extends to the modulation of several major signal transduction cascades that govern cellular proliferation, survival, and differentiation. The compound has been shown to modify Wnt-TCF signaling, a pathway frequently dysregulated in colorectal and other cancers, and to interfere with the mevalonate pathway, which is essential for the post-translational modification and membrane localization of small GTPases. Through these effects, lycopene contributes to the inactivation of Ras signaling, a critical oncogenic driver in many human cancers [54]. Additionally, lycopene suppresses the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling axis, which is frequently hyperactivated in cancer cells and promotes cell survival and growth. The inhibition of platelet-derived growth factor-induced signaling represents another mechanism through which lycopene may exert anti-tumor effects, particularly in the context of tumor-stromal interactions [54].

The anti-inflammatory effects of lycopene are mediated in part through the inhibition of nuclear factor-kappa B signaling, a transcription factor that regulates the expression of numerous pro-inflammatory and anti-apoptotic genes [55]. Simultaneously, lycopene modulates nuclear factor erythroid 2-related factor 2-mediated oxidative stress responses, enhancing the cellular capacity to counteract oxidative damage. Additional molecular targets include the downregulation of proliferating cell nuclear antigen, an essential component of the DNA replication machinery; cyclooxygenase-2, a key enzyme in prostaglandin synthesis; prostaglandin E₂, a pro-inflammatory lipid mediator; and phosphorylated extracellular signal-regulated kinase 1/2, a component of the mitogen-activated protein kinase cascade [54-56]. Furthermore, lycopene has been shown to reduce the phosphorylation of glycogen synthase kinase-3 β and to upregulate the expression of E-cadherin, a cell adhesion molecule whose loss is associated with epithelial-mesenchymal transition and metastatic progression [54-56].

Figure 5 provides a comprehensive diagram summarizing the molecular targets and signaling pathways

modulated by lycopene. The illustration presents an integrated view of lycopene's effects on insulin-like growth factor signaling, sex steroid receptor activity, the mevalonate and Ras pathways, the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin and mitogen-activated protein kinase cascades, and the nuclear factor-kappa B and nuclear factor erythroid 2-related factor 2 signaling axes. The figure also depicts the downstream effectors of these pathways, including proliferating cell nuclear antigen, cyclooxygenase-2, prostaglandin E₂, extracellular signal-regulated kinase 1/2, glycogen synthase kinase-3 β , and E-cadherin. By visually integrating these diverse molecular targets, Figure 5 illustrates the remarkable capacity of lycopene to intersect with multiple signaling networks simultaneously, providing a mechanistic basis for its pleiotropic anti-cancer effects.

8. CONCLUSION

The body of evidence presented in this review firmly establishes lycopene as more than a simple antioxidant; it is a complex, bioactive molecule with a remarkable capacity to influence the fundamental processes of carcinogenesis. While its role in quenching free radicals and mitigating oxidative DNA damage is a well-documented cornerstone of its chemopreventive activity, the true therapeutic potential of lycopene lies in its ability to orchestrate a cascade of cellular events that directly counter tumor progression. Our analysis reveals a compound capable of exerting precise control over the cell cycle, effectively halting the uncontrolled proliferation of malignant cells by modulating the expression of cyclins and cyclin-dependent kinase inhibitors. Simultaneously, lycopene acts as a potent inducer of programmed cell death, destabilizing mitochondrial membrane potential and triggering the release of pro-apoptotic factors. This dual action of anti-proliferation and pro-apoptosis is a hallmark of an effective anticancer agent. Moreover, lycopene's influence extends to the tumor microenvironment and hormonal axes. It demonstrates a capacity to dampen chronic inflammation, a known driver of cancer, by interfering with pro-inflammatory cytokine signaling and transcription factors like NF- κ B. Its ability to modulate estrogen and androgen receptor activity, alongside the insulin-like growth factor (IGF) signaling pathway, positions it as a relevant agent for hormone-sensitive cancers such as those of the breast and prostate. This ability to intersect with multiple, often redundant, cancer-promoting pathways suggests that lycopene's efficacy stems from a holistic, network-level interference with cancer biology. In conclusion, lycopene stands out as a promising, multi-targeted natural agent. Its potential lies not in replacing conventional therapies but in complementing them, potentially allowing for lower doses of traditional chemotherapeutics, mitigating their associated toxicities, and improving overall patient outcomes. The simple dietary inclusion of lycopene-rich foods, particularly tomatoes, may represent a foundational, accessible strategy for cancer risk

reduction, but its full therapeutic potential warrants further investigation and clinical validation.

9. FUTURE DIRECTIONS

While the preclinical data on lycopene is compelling, a significant translational gap remains before it can be confidently integrated into clinical oncology. The journey from bench to bedside requires a concerted effort to address several critical research priorities. One of the most pressing challenges is the issue of bioavailability. The all-trans isomer of lycopene, which is the primary form found in raw tomatoes, is poorly absorbed by the human body. While thermal processing and the presence of dietary fats can enhance its absorption and promote isomerization to the more bioavailable cis-isomers, we lack standardized protocols for preparing lycopene formulations that guarantee consistent and predictable plasma levels. Future research must prioritize the development of novel delivery systems, such as nanoparticle encapsulation, lipid-based carriers, or its combination with absorption enhancers, to ensure that therapeutic concentrations can be reliably achieved in target tissues.

Furthermore, the field must move beyond reductionist *in vitro* models. The complex interplay between lycopene,

the gut microbiome, and the immune system is largely unexplored. Given that lycopene is ingested, its interaction with the intestinal microbiota could yield novel bioactive metabolites with distinct or enhanced anticancer properties. Similarly, the immunomodulatory effects of lycopene, particularly its influence on tumor-infiltrating lymphocytes, macrophage polarization, and the broader anti-tumor immune response, warrant rigorous investigation. Understanding these systemic effects is crucial, as the future of cancer therapy increasingly hinges on harnessing the body's own immune system.

A pivotal next step involves the design and execution of well-controlled, randomized clinical trials. Many existing human studies are observational in nature, correlating dietary intake with cancer risk, and are often confounded by other lifestyle factors. Future trials should move towards interventional designs, enrolling specific patient cohorts, such as those with early-stage prostate cancer on active surveillance or individuals at high genetic risk for certain cancers. These trials should employ rigorous endpoints, moving beyond simple biomarker analysis to include clinically meaningful outcomes like time to progression, recurrence rates, and overall survival.

Another critical area is the investigation of combinatorial strategies. The future of oncology is polytherapy, and lycopene's multi-targeted mechanism makes it an ideal candidate for combination regimens.




Fig. 5. Comprehensive diagram of molecular targets and signaling pathways modulated by lycopene. Lycopene affects insulin-like growth factor signaling, sex steroid receptor activity, the mevalonate and Ras pathways, PI3K/Akt/mTOR and MAPK cascades, and NF- κ B and Nrf2 signaling, leading to downstream modulation of PCNA, COX-2, PGE₂, ERK1/2, GSK-3 β , and E-cadherin.

Preclinical studies have already hinted at synergistic effects with compounds like capsaicin and with standard chemotherapeutics. Systematic studies are needed to explore its potential to sensitize resistant tumors to conventional drugs, to protect healthy tissues from the toxic effects of radiation and chemotherapy, and to enhance the efficacy of emerging immunotherapies. Finally, the era of personalized medicine necessitates a deeper exploration into pharmacogenomics. Identifying genetic polymorphisms that influence lycopene metabolism, absorption, or its molecular targets could allow for the stratification of patients who would most likely benefit from lycopene-based interventions. By addressing these key areas, bioavailability, systemic mechanisms, rigorous clinical validation, combinatorial strategies, and personalized approaches, the scientific community can unlock the full potential of this promising natural compound and translate decades of promising preclinical research into tangible clinical benefits for cancer patients.

DECLARATIONS

Ethical Approval

We affirm that this manuscript is an original work, has not been previously published, and is not currently under consideration for publication in any other journal or conference proceedings. All authors have reviewed and approved the manuscript, and the order of authorship has been mutually agreed upon.

Funding

Not applicable

Availability of data and material

All of the data obtained or analyzed during this study is included in the report that was submitted.

Conflicts of Interest

The authors declare that they have no financial or personal interests that could have influenced the research and findings presented in this paper. The authors alone are responsible for the content and writing of this article.

Authors' contributions

All authors contributed equally to this work.

REFERENCE

- [1] Shi, J. and Le Maguer, M. **2000**. Lycopene in tomatoes: Chemical and physical properties affected by food processing, *Critical Reviews in Food Science and Nutrition*, 40(1), PP. 1–42.
- [2] Stahl, W. and Sies, H. **1996**. Lycopene: A biologically important carotenoid for humans?, *Archives of Biochemistry and Biophysics*, 336(1), PP. 1–9.
- [3] Rao, A.V. and Agarwal, S. **1999**. Role of antioxidant lycopene in cancer and heart disease, *Journal of the American College of Nutrition*, 19(5), PP. 563–569.
- [4] Di Mascio, P., Kaiser, S. and Sies, H. **1989**. Lycopene as the most efficient biological carotenoid singlet oxygen quencher, *Archives of Biochemistry and Biophysics*, 274(2), PP. 532–538.
- [5] Hamza, A.A., Heeba, G.H., Hamza, S. and Abdalla, A.M. **2018**. Lycopene exerts anti-inflammatory and antioxidant effects in lipopolysaccharide-induced oxidative stress model, *Biomedicine and Pharmacotherapy*, 109, PP. 196–203.
- [6] Palozza, P., Simone, R., Catalano, A. and Mele, M.C. **2010**. Tomato lycopene and inflammatory cascade: basic interactions and clinical implications, *Current Medicinal Chemistry*, 17(23), PP. 2547–2563.
- [7] Qu, M., Zhou, Z., Chen, C., Li, M., Pei, L., Chu, F., Yang, J. and Wang, Y. **2016**. Lycopene protects against β -amyloid-induced neuroinflammation by inhibiting NF- κ B signaling pathway, *Neurochemical Research*, 41(7), PP. 1673–1684.
- [8] Yonar, M.E., Yonar, S.M., Ural, M.Ş. and Silici, S. **2014**. Protective role of lycopene against oxidative stress and apoptosis in brain tissue induced by toxic agents, *Experimental and Toxicologic Pathology*, 66(6), PP. 245–252.
- [9] Klaunig, J.E., Kamendulis, L.M. and Hocevar, B.A. **2010**. Oxidative stress and oxidative damage in carcinogenesis, *Toxicologic Pathology*, 38(1), PP. 96–109.
- [10] Valko, M., Rhodes, C.J., Moncol, J., Izakovic, M. and Mazur, M. **2006**. Free radicals, metals and antioxidants in oxidative stress-induced cancer, *Chemico-Biological Interactions*, 160(1), PP. 1–40.
- [11] Agarwal, S. and Rao, A.V. **2000**. Tomato lycopene and its role in human health and chronic diseases, *Canadian Medical Association Journal*, 163(6), PP. 739–744.
- [12] Giovannucci, E. **1999**. Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature, *Journal of the National Cancer Institute*, 91(4), PP. 317–331.
- [13] Sharoni, Y., Danilenko, M., Dubi, N., Ben-Dor, A. and Levy, J. **2004**. Carotenoids and apoptosis, *Apoptosis*, 9(3), PP. 237–250.

- [14] Teodoro, A.J., Oliveira, F.L., Martins, N.B., Maia, G.A., Martucci, R.B. and Borojevic, R. **2012**. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines, *Cancer Cell International*, 12(1), PP. 36.
- [15] Venier, N.A., Yamamoto, T., Sugar, L.M., Adomat, H., Fleshner, N.E., Klotz, L.H. and Venkateswaran, V. **2012**. Lycopene enhances the anti-proliferative and pro-apoptotic effects of capsaicin in prostate cancer cell lines, *The Journal of Nutritional Biochemistry*, 23(7), PP. 781–789.
- [16] Salman, H., Bergman, M., Djaldetti, M., Bessler, H. **2007**. Lycopene affects proliferation and apoptosis of four malignant cell lines, *Biomedicine and Pharmacotherapy*, 61(6), PP. 366–369.
- [17] Amir, H., Karas, M., Giat, J., Danilenko, M., Levy, R., Yermiah, T., Levy, J. and Sharoni, Y. **1999**. Lycopene and 1,25-dihydroxyvitamin D₃ cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells, *Nutrition and Cancer*, 33(1), PP. 105–112.
- [18] Müller, K., Carpenter, K.L.H., Challis, I.R., Skepper, J.N. and Arends, M.J. **2002**. Carotenoids induce apoptosis in the T-lymphoblast cell line Jurkat E6, *British Journal of Nutrition*, 88(6), PP. 593–599.
- [19] Simon, H.U., Haj-Yehia, A. and Levi-Schaffer, F. **2000**. Role of reactive oxygen species (ROS) in apoptosis induction, *Apoptosis*, 5(5), PP. 415–418.
- [20] Brenneisen, P., Steinbrenner, H. and Sies, H. **2005**. Hydrogen peroxide, oxidative stress, and signal transduction, *Annual Review of Pharmacology and Toxicology*, 45, PP. 123–152.
- [21] Spivak, J.L. **2011**. The blood in systemic disorders, *The Lancet*, 377(9764), PP. 138–149.
- [22] Adachi, T., Pimentel, D.R., Heibeck, T., Hou, X., Lee, Y.J., Jiang, B., Ido, Y. and Cohen, R.A. **2004**. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells, *The Journal of Biological Chemistry*, 279(29), PP. 29857–29862.
- [23] Duracková, Z. **2010**. Some current insights into oxidative stress, *Physiological Research*, 59(4), PP. 459–469.
- [24] Silva, G.A. **2018**. Oxidative stress and its implications in human health, *Journal of Biomedical Science*, 25(1), PP. 1–13.
- [25] Schafer, F.Q. and Buettner, G.R. **2001**. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple, *Free Radical Biology and Medicine*, 30(11), PP. 1191–1212.
- [26] Shobha, R.I., Prashanth, K.V., and Ramesh, C.K. **2013**. Role of antioxidants in the prevention of cancer, *International Journal of Pharmaceutical Sciences Review and Research*, 21(1), PP. 275–280.
- [27] Hussain, S.P., Hofseth, L.J. and Harris, C.C. **2003**. Radical causes of cancer, *Nature Reviews Cancer*, 3(4), PP. 276–285.
- [28] Miki, W. **1991**. Biological functions and activities of animal carotenoids, *Pure and Applied Chemistry*, 63(1), PP. 141–146.
- [29] Cao, G., Booth, S.L., Sadowski, J.A. and Prior, R.L. **1998**. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables, *The American Journal of Clinical Nutrition*, 68(5), PP. 1081–1087.
- [30] Purnima, A., Kothari, S. and Kothari, S.L. **2012**. Effect of lycopene supplementation on lipid peroxidation and oxidative stress, *Journal of Clinical and Diagnostic Research*, 6(3), PP. 443–446.
- [31] Rahman, I., Biswas, S.K. and Kirkham, P.A. **2006**. Regulation of inflammation and redox signaling by dietary polyphenols, *Biochemical Pharmacology*, 72(11), PP. 1439–1452.
- [32] Gagandeep, S., Dhanalakshmi, S., Mendiz, E., Rao, A.R. and Kale, R.K. **2003**. Chemopreventive effects of *Cuminum cyminum* in chemically induced forestomach and uterine cervix tumors in murine model systems, *Nutrition and Cancer*, 47(2), PP. 171–180.
- [33] Bhairavabhotla, R., Verma, A., and Krishna, S. **2007**. Cytokine gene expression in cervical cancer progression, *Gynecologic Oncology*, 104(2), PP. 495–502.
- [34] Koshaar, I., Thakur, N., Salhan, S., Batra, S., Singh, V., Sharma, A., Sodhani, P., Das, B.C., Sarkar, D.P. and Bharadwaj, M. **2007**. TNF α -308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population, *Analytical Cellular Pathology*, 29(3), PP. 249–257.
- [35] Bequet-Romero, M. and Lopez-Ocejo, O. **2000**. Tumor necrosis factor- α and human papillomavirus infection: Role in cervical carcinogenesis, *Journal of the National Cancer Institute*, 92(3), PP. 217–224.
- [36] Kroeger, K.M., Carville, K.S. and Abraham, L.J. **2000**. The -308 tumor necrosis factor- α promoter polymorphism effects transcription, *Molecular Immunology*, 37(9), PP. 523–530.

- [37] Eksteen, B., Miles, A.E., Grant, A.J. and Adams, D.H. **2001**. Lymphocyte homing in the pathogenesis of hepatic inflammation, *Gut*, 48(5), PP. 692–700.
- [38] Tjong, M.Y., van der Vange, N., ten Kate, F.J.W., Tjong-A-Hung, S.P., ter Schegget, J., Burger, M.P.M. and Out, T.A. **2001**. Increased cytokine levels in cervicovaginal washings from patients with cervical neoplasia, *Cytokine*, 14(6), PP. 357–360.
- [39] Mirahmadi, M., Baradaran, B., Alipour, S. and Aghebati-Maleki, A. **2020**. Lycopene inhibits proliferation and induces cell cycle arrest in prostate cancer cells: In vitro and in vivo studies, *Journal of Cellular Biochemistry*, 121(5–6), PP. 3151–3161.
- [40] Tang, L., Jin, T., Zeng, X. and Wang, J.S. **2005**. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in vivo, *Journal of Nutrition*, 135(2), PP. 287–290.
- [41] Chen, Y.Q., Hsieh, J.T., Yao, F., Fang, B., Pong, R.C., Cipriano, S.C. and Kreputat, F. **1999**. Induction of apoptosis and G2/M cell cycle arrest by DCC, *Oncogene*, 18(17), pp. 2747–2754.
- [42] Hwang, E.S., Bowen, P.E., and Liu, R.H. **2004**. Lycopene induces cell cycle arrest and apoptosis in human cancer cells, *Nutrition and Cancer*, 50(1), PP. 97–103.
- [43] Palozza, P., Serini, S., Torsello, A., Boninsegna, A., Maggiano, N., and Calviello, G. **2007**. Lycopene induces apoptosis in human colon cancer cells via modulation of Bcl-2 family proteins, *Carcinogenesis*, 28(8), PP. 1788–1795.
- [44] Wang, A., and G.R. Gardner. **2007**. Lycopene inhibits growth of human prostate cancer cells through Akt signaling modulation, *Cancer Letters*, 251(2), PP. 167–175.
- [45] Palozza, P., Serini, S., Torsello, A., Boninsegna, A., Maggiano, N., Calviello, G. **2010**. Lycopene regulates cell cycle and apoptosis-related proteins in cancer cells, *Journal of Nutritional Biochemistry*, 21(12), PP. 1155–1164.
- [46] Nahum, A., Hirsch, K., Danilenko, M., Watts, C.K.W., Prall, O.W.J., Levy, J. and Sharoni, Y. **2001**. Lycopene inhibits growth of human prostate carcinoma cells via modulation of cell cycle proteins, *Experimental Biology and Medicine*, 226(10), PP. 1016–1022.
- [47] Tang, F.Y., Shih, C.J., Cheng, L.H., Ho, H.J. and Chen, H.J. **2008**. Lycopene induces G₁/S arrest in human breast cancer cells through cyclin regulation, *Carcinogenesis*, 29(4), PP. 831–838.
- [48] Hantz, H.L., Shih, C.J., Cheng, L.H., Ho, H.J. and Chen, H.J. **2005**. Lycopene induces apoptosis in human prostate cancer cells via mitochondrial pathway, *Experimental Biology and Medicine*, 230(9), PP. 604–611.
- [49] Hirsch, K., Atzmon, A., Danilenko, M., Levy, J. and Sharoni, Y. **2007**. Lycopene inhibits estrogen-induced proliferation of breast and endometrial cancer cells via ER α and ER β modulation, *Carcinogenesis*, 28(8), PP. 1745–1752.
- [50] Karas, M., Amir, H., Fishman, D., Danilenko, M., Segal, S., Nahum, A., Koifman, A., Giat, Y., Levy, J. and Sharoni, Y. **2000**. Lycopene modulates the insulin-like growth factor system in humans: Implications for cancer risk, *Cancer Epidemiology, Biomarkers & Prevention*, 9(1), PP. 21–28.
- [51] Kanagaraj, P., Vijayababu, M.R., Arunkumar, A., Ilangoan, R., Aruldas, M.M. and Arunakaran, J. **2007**. Lycopene modulates IGF-I signaling and inhibits proliferation of cancer cells, *Nutrition and Cancer*, 57(2), PP. 172–179.
- [52] Nahum, A., Hirsch, K., Danilenko, M., Watts, C.K.W., Prall, O.W.J., Levy, J. and Sharoni, Y. **2006**. Lycopene inhibits IGF-I mediated cell proliferation and modulates IGF system in cancer cells, *Experimental Biology and Medicine*, 231(7), PP. 1238–1245.
- [53] Levy, J., Bosin, E., Feldman, B., Giat, Y., Miinster, A., Danilenko, M. and Sharoni, Y. **1995**. Insulin-like growth factor I receptor and cell proliferation: Modulation by dietary factors, *Cancer Research*, 55(11), PP. 2386–2392.
- [54] Wu, W.B., Liao, Y.C., Huang, Y.T., Hsu, C.L. and Wang, C.J. **2007**. Lycopene inhibits PDGF-BB-induced signaling and regulates E-cadherin in cancer cells, *Carcinogenesis*, 28(7), pp. 1410–1417.
- [55] Lin, M.C., Wang, E.J., Lee, C., Chin, K.T., Liu, D., Chiu, J.F. and Yang, V.C. **2007**. Lycopene inhibits NF- κ B activation and suppresses inflammatory response in cancer cells, *Journal of Nutritional Biochemistry*, 18(8), pp. 531–538.
- [56] Tang, F.Y., Pai, M.H., Wang, X.D. and Chen, H.J. **2009**. Lycopene suppresses cell proliferation and modulates signaling pathways in breast cancer cells, *Journal of Agricultural and Food Chemistry*, 57(11), PP. 4835–4841.